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Poster Session I S251patients were re-started on a tyrosine kinase inhibitor (Imatinib -5,
Dasatinib -1). One patient had delayed recovery of blood counts
and was not restarted on a TKI. One patient relapsed 4 months
post PBSCT and died due to refractory disease. Remaining patients
remain alive at median 26 months (range 12-86) in complete molec-
ular remission. Of note the patient that never received post-trans-
plant TKI remains in complete molecular remission 86 months
following PBSCT.
Conclusion: Autologous stem cell transplantation in combination
with tyrosine kinase inhibition can provide long term durable remis-
sions in patients with Ph+ ALLwho are unable to undergo allogeneic
stem cell transplantation.
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PLANTATION WITH AND WITHOUT METAIODOBENZYLGUANIDINE
(MIBG) IN PATIENTS WITH HIGH RISK NEUROBLASTOMA
Hamidieh, A.A.1, Beigi, D.2, Fallahi, B.2, Behfar, M.1, Jalili, M.1,
Hamdi, A.1, Hosseini, A.1, Ghavamzadeh, A.1 1Tehran University of
Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran University
of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Autologous Hematopoietic Stem Cell transplantation
(auto-HSCT) has been considered for treatment of patients with
high risk neuroblastoma. In this study we compared two main
strategies of auto-HSCT for patients with high risk neuroblastoma:
auto-HSCT alone in patient with negative diagnostic MIBG and
auto-HSCT with therapeutic MIBG before HSCT in patient with
positive diagnostic MIBG.
Methods: The results of 14 patients with high risk neuroblastoma
who underwent auto-HSCT at our center from 2008 to 2011,
were analyzed. Median age at transplantation was 4.5 years (range
5 2-7, 50% male). N-Myc amplification was positive in 9 patients
(64.3%). Diagnostic MIBG was asked at first visit from all patients
who were referred to our center for HSCT. Patients were divided
into two groups according to the result of diagnostic MIBG:
MIBG-avid (n 5 6) and non MIBG-avid (n 5 8). MIBG-avid pa-
tients received 131I-MIBG (12 mci/kg) on day 21 before transplanta-
tion. The conditioning regimen used in all patients consisted of
etoposide (1200mg/m2 total dose divided for 5 days), carboplatin
(1500mg/m2 total dose divided for 5 days), and melphalan (210mg/
m2 total dose divided for 3 days). The source of stem cells was pe-
ripheral blood in patients. The median numbers of MNC and
CD34 injected were 10.71x108/kg /kg, 1.7x106/kg, respectively. All
patients received 13-cis-retinoic acid (120-160 mg/m2 2 weeks per
month) from day +60 to one year after transplantation.
Results: Engraftment occurred in all patients. The median time to
neutrophil and platelet engraftment were 13 (10-18 days) and 17
days (13-21 days), respectively that was not significantly different
between two groups. No severe side effects (like neutropenia, throm-
bocytopenia and mucusitis) were observed in any patients in MIBG-
avid group. With a median follow-up time of 13 months (2-35
months), 2 patients (33.3%) relapsed in MIBG-avid group (both
died) and 5 patients (62.5%) relapsed in non MIBG-avid group (4
of them died).
Conclusion:Despite nonsignificant difference between two groups,
MIBG-avid patients seem to have better survival and lower relapse
rate. Therefore, much greater number of cases is needed to clarify
the role of MIBG therapy in pre-transplant conditioning regimen
for autologous hematopoietic stem cell transplantation in high risk
neuroblastoma patients.127
COMPARISON OF BUSULFAN +MELPHALAN TOMELPHALAN 200 MG/M2
AS PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN
MULTIPLE MYELOMA
Ahmed, S., Dinh, Y., Rondon, G., Andersson, B., Jones, R., Bashir, Q.,
Shah, N., Popat, U., Champlin, R.E., Qazilbash, M.H., Kebriaei, P.
The University of Texas, M.D. Anderson Cancer Center, Houston, TX
Background:High-dose chemotherapy with melphalan 200 mg/m2
(Mel 200) followed by autologous hematopoietic stem cell transplan-tation (auto-HCT) is the standard treatment for transplant-eligible
patients (pts) withmultiplemyeloma (MM).Most patients eventually
relapse after auto-HCT and in efforts to improve the efficacy of the
preparative regimen, several groups have evaluated the combination
of busulfan (Bu) and melphalan (Mel). We studied the safety and ef-
ficacy of a combination of Bu and Mel (Bu-Mel) in patients with ad-
vanced lymphoid malignancies, including MM. (Kebriaei P, et al.,
Biol Blood Marrow Transplant 2011; 17: 412-420). In this study
we compared outcomes of patients with MM who received Bu-Mel
with a control group of patients who received Mel 200 for auto-
HCT for MM.
Methods: We identified 30 patients with MM in first remission
who received Bu-Mel followed by auto-HCT between 1/2005
and 10/2010. They were compared to a control group (4:1) of
120 patients with MM who received Mel 200 as conditioning reg-
imen for auto-HCT. The groups were matched for year of auto-
HCT, age at auto-HCT (+/- 4 yrs), cytogenetic abnormalities,
and disease status at auto-HCT. The primary objective was to
study impact of conditioning regimens on complete (CR) and
overall response rate (ORR), progression-free (PFS) and overall
survival (OS).
Results: Patient characteristics and major outcomes are summa-
rized in the attached Table. Bu-Mel and Mel 200 groups were
similar in median age, renal function and chemosensitivity at auto-
HCT, and time from diagnosis to auto-HCT (Table). Median
time to neutrophil engraftment in both groups was 10 days (p 5
0.8). There was no significant difference in 100-day transplant-
related mortality (0% vs. 0.8%, p 5 0.2) or grade 2-4 non-he-
matologic toxicity between Bu-Mel and Mel 200 (80% vs. 66%, p
5 0.18) or veno-occlusive disease (none in either group). CR rates
in Bu-Mel and Mel 200 were 30% vs. 34% (p 5 0.82, Table).
Median follow up was 27.3 months. Median PFS for Bu-Mel and
Mel 200 were 24.1 and 26.2 months, respectively (p 5 0.43,
Figure 1). Median OS for Bu-Mel and Mel 200 has not yet been
reached (p 5 0.24, Figure 2).
Conclusions: In this large single center study with long follow up,
we demonstrated that a preparative regimen of Bu-Mel is compara-
ble to Mel 200 in safety and efficacy. The two regimens will be com-
pared in a prospective, randomized trial.
Table. Patient Characteristics/Outcomes
Bu-Mel (n 5 30) Mel200 (n 5 120) pMales 17 68 1.00
Median Age 52.5 52 0.19
Abn Cytogenetics 12 48 1.00
High Risk CG 2 8 1.00
Serum Creat > 1.5 at TP 1 8 0.68
Median Interval Dx to TP 6.8 mo 6.7 mo 0.44
Median CD34 4.63 4.76 0.31
Chemosensitive (>/ 5 atTP) 13% 9% 0.50
Median days to engraftment
ANC ./ 5 500
10 10 0.81CR 9, 30% 41, 34% 0.82
CR + VGPR 20, 66% 72, 60% 0.53
ORR 27, 90% 110, 83% 0.57
100-day TRM 0 1, 0.8% 0.20
Grade 2-4 AE 24, 80% 79, 66% 0.18
Median PFS 24.1 mo 26.2 mo 0.43
Median OS not reached not reached 0.24128
QUALIFICATION OF CORD BLOOD UNITS FOR AN AUTOLOGOUS
INFUSION PROGRAM FOR PEDIATRIC PATIENTS WITH ACQUIRED BRAIN
INJURIES
Allison-Thacker, J., Fitzgerald, A., Sun, J., McLaughlin, C., Waters-
Pick, B., Vinesett, R., Kurtzberg, J. Duke University Medical Center,
Durham, NC
Autologous umbilical cord blood (CB) infusion for the treatment
of brain injuries in young children has been studied by the Pediatric
Blood and Marrow Transplant (PBMT) Program at Duke Univer-
sity Medical Center since 2004. The majority of infusions have
been used to treat children with Hypoxic Ischemic Encephalopathy
